An FDA advisory panel has recommended market approval for TransMedic’s device used to perfuse lungs prior to transplantation. Xvivo Perfusion has previously been the sole actor in the market for warm perfusion of lungs in the United States, but will now face competition. We believe that Xvivo Perfusion has a stronger product offering and see no reason to revise our estimates due to the event.